Biotech Values

[TwoNE1]

STML: Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial, the Company Raises Money

Stemline's SL-401 has demonstrated robust overall tumor response rates in its clinical trial but the drug is also now tied to three patient deaths from capillary leak syndrome.

Adam Feuerstein
Feb 2, 2017 6:00 AM EST

Investors who bought into a $45 million Stemline Therapeutics (STML) stock offering on Jan. 19 were not told that one day prior to the financing, a cancer patient in a clinical trial died from a severe side effect, a type of low blood pressure, tied to the company's drug SL-401.

Stemline has disclosed two previous patient deaths related to the same SL-401 toxicity -- capillary leak syndrome.

The third death in Stemline's SL-401 study due to capillary leak syndrome, not yet reported by the company but confirmed by a member of the patient's family, is potentially troubling because it occurred after Stemline had already increased safety monitoring and added new dosing rules to reduce the incidence and severity of the side effect.

More at:
https://www.thestreet.com/story/13975695/1/side-effect-kills-cancer-patient-in-stemline-therapeutics-drug-trial-the-company-raises-money.html?puc=yahoo&cm_ven=YAHOO